Niche pharma company HRA expands into Spain
pharmafile | January 25, 2010 | News story | Sales and Marketing | HRA Pharma, Spain
French reproductive health and endocrinology company HRA Pharma has set up commercial operations in Spain, its fifth European base to date.
Laboratorios HRA Pharma Espana follows in the footsteps of subsidiaries in Germany, Italy and the UK, and will be led by general manager Ignacio Garcia.
He joins HRA following a 20-year career at Schering and Bayer Schering Pharma in Spain, where he was most recently head of the Women’s Health Business Unit.
Laboratorios HRA Pharma Espana is located near the heart of Madrid’s financial district and will concentrate on supporting HRA’s new generation emergency contraception, ellaOne (ulipristal acetate).
“Spain represents the third largest market in emergency contraception in Europe and we are excited about the tremendous opportunities that this crucial market, coupled with our experienced Spanish team, will bring to women’s health,” said Dr Erin Gainer, HRA’s chief executive.
“We are committed to making ellaOne available to women throughout Europe one country at a time and, in parallel, to reinforcing our position as an independent company at the heart of niche products such as Lysodren in target markets.”
Indicated for emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure ellaOne was launched in France, Germany and the UK last year.
Its active ingredient is a synthetic selective progesterone receptor modulator and it is the first molecule to have been specifically designed and developed for use as an oral emergency contraceptive.
Laboratorios HRA Pharma Espana will handle sales, marketing and distribution for Lysodren, HRA Pharma’s orphan drug for the symptomatic treatment of advanced adrenal cortical carcinoma.
Lysodren and ellaOne will be sold in Spain by HRA’s in-house, dedicated sales force.
The European launch of ellaOne is the first step in the international commercialisation of the product, which HRA plans to rollout under the brand names ellaOne and ella.
Related Content
Spain secures 31.6 million doses of AstraZeneca’s COVID-19 vaccine
AstraZeneca continues to forge agreements with national governments to deliver its vaccine against COVID-19, with …
€10.2 billion lost every year across the EU due to fake medicines
A report commissioned by the European Union Intellectual Property Office has shown that a staggering …
Six Code breaches for HRA Pharma
HRA Pharma has been slammed by the PMCPA after breaching six clauses of the ABPI …
